Kura Oncology, Inc. (KURA)
NASDAQ: KURA · IEX Real-Time Price · USD
20.59
+0.31 (1.53%)
At close: May 2, 2024, 4:00 PM
19.00
-1.59 (-7.72%)
After-hours: May 2, 2024, 7:37 PM EDT
Kura Oncology Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
142
Market Cap
1.57B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.06B |
Taro Pharmaceutical Industries | 610.83M |
U.S. Physical Therapy | 604.80M |
Veracyte | 361.05M |
Zai Lab | 266.72M |
ADMA Biologics | 258.22M |
Ardelyx | 124.46M |
KURA News
- 11 hours ago - Kura Oncology Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 7 days ago - Kura Oncology to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 10 days ago - Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML - GlobeNewsWire
- 22 days ago - Kura Oncology to Participate in Stifel Targeted Oncology Forum - GlobeNewsWire
- 27 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma - GlobeNewsWire
- 2 months ago - Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia - GlobeNewsWire